Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-306: tarlatamab maintenance after chemoradiotherapy in limited-stage small-cell lung cancer
2023-506235-15-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Nov 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Tarlatamab with Placebo for tarlatamab (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Nov 2024; status: authorised.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2023-506235-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506235-15-00.